Alpine Immune Sciences, Inc.
NASDAQ: ALPN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mitchell H. Gold
- Employees
- 142
- Headquarters
- Seattle, United States
- IPO year
- 2015
- Market cap
- $4.5B
- Website
- https://www.alpineimmunesciences.com
Loading ALPN…
Loading profile data…Frequently asked questions about ALPN
What does Alpine Immune Sciences, Inc. (ALPN) do?
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist...
Where does ALPN trade?
Alpine Immune Sciences, Inc. (ALPN) trades on the NASDAQ Global Market.
What sector is ALPN in?
Alpine Immune Sciences, Inc. (ALPN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Alpine Immune Sciences, Inc.?
Mitchell H. Gold is the chief executive officer of Alpine Immune Sciences, Inc. (ALPN).
Where is Alpine Immune Sciences, Inc. headquartered?
Alpine Immune Sciences, Inc. is headquartered in United States.
Does ALPN pay a dividend?
Alpine Immune Sciences, Inc. (ALPN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ALPN go public?
Alpine Immune Sciences, Inc. (ALPN) completed its initial public offering in 2015.